Designability Need Our Help

Designability has reached out to TreatSMA to say they have lots of Wizzybugs available and if children are in need of independent mobility from the ages roughly of 14 months to 4/5 years old then please get in contact with them.

Apply for a Free Wizzybug

They are also in the process of developing new ideas.

Designability has asked if the SMA community would answer a few questions about wheelchair insurance.

Please put your answers in a email to lucy.frost@treatsma.uk numbering 1 to 5.

1. Do you have wheelchair insurance?
2. How much does your annual wheelchair insurance cost.
3. How much does it cost to get your wheelchair insured if you take it abroad on average?
4. Does the cost of wheelchair insurance deter you from going abroad?
5. Does your child’s school or your college/university/workplace require your wheelchair to be insured?

Please answer as they really want to help and continue to give a free service.

Thanks

TreatSMA

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more